A panelist discusses how the COCOON study demonstrated that enhanced dermatologic management significantly reduces the ...

Johnson & Johnson’s (J&J’s) Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by one year above the standard of care (SOC) in ...

"The survival curve tells a clear story. RYBREVANT plus LAZCLUZE helps patients live longer, and the benefit keeps growing over time," said trial investigator Professor Nicolas Girard*, M.D., Ph.D ...

Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC). J&J’s pharma arm, Janssen ...

Amivantamab-vmjw plus lazertinib significantly improved OS for certain patients with advanced NSCLC compared with osimertinib. The combination also reduced risk for intracranial progression and ...

The study compared Rybrevant (amivantamab) plus Lazcluze (lazertinib) to osimertinib as a first-line treatment. The data, presented at the 2025 European Lung Cancer Congress, showed that the ...

PARIS — Final overall survival results from the phase 3 MARIPOSA study showed that the first-line amivantamab plus lazertinib combination extended overall survival notably more than osimertinib ...

The combination J&J’s Rybrevant (amivantamab) with Yuhan Corp-partnered Leclaza (lazertinib) has been shown to be more effective than Tagrisso (osimertinib) on its own at extending progression ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...